DongKoo Bio & Pharma Co., Ltd.

KOSDAQ:A006620 Stock Report

Market Cap: ₩132.7b

DongKoo Bio & Pharma Past Earnings Performance

Past criteria checks 4/6

DongKoo Bio & Pharma has been growing earnings at an average annual rate of 15.4%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 16.3% per year. DongKoo Bio & Pharma's return on equity is 13.4%, and it has net margins of 6%.

Key information

15.4%

Earnings growth rate

16.4%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate16.3%
Return on equity13.4%
Net Margin6.0%
Last Earnings Update30 Sep 2024

Recent past performance updates

We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings

Mar 27
We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings

Recent updates

DongKoo Bio & Pharma (KOSDAQ:006620) Has A Pretty Healthy Balance Sheet

Dec 16
DongKoo Bio & Pharma (KOSDAQ:006620) Has A Pretty Healthy Balance Sheet

More Unpleasant Surprises Could Be In Store For DongKoo Bio & Pharma Co., Ltd.'s (KOSDAQ:006620) Shares After Tumbling 32%

Aug 23
More Unpleasant Surprises Could Be In Store For DongKoo Bio & Pharma Co., Ltd.'s (KOSDAQ:006620) Shares After Tumbling 32%

Should You Be Adding DongKoo Bio & Pharma (KOSDAQ:006620) To Your Watchlist Today?

Jul 25
Should You Be Adding DongKoo Bio & Pharma (KOSDAQ:006620) To Your Watchlist Today?

We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings

Mar 27
We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings

Revenue & Expenses Breakdown

How DongKoo Bio & Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A006620 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24253,71015,337126,1579,641
30 Jun 24240,39513,005120,69110,378
31 Mar 24231,40914,307114,07510,449
31 Dec 23215,68611,812105,62110,752
30 Sep 23201,7156,823100,5649,220
30 Jun 23199,5078,68597,7848,361
31 Mar 23196,1746,25194,3808,326
31 Dec 22194,9886,61491,6388,258
30 Sep 22187,1098,40187,1578,263
30 Jun 22176,8587,64181,8029,131
31 Mar 22166,04511,36577,5119,702
31 Dec 21155,1499,32773,09310,114
30 Sep 21149,0317,45570,36810,698
30 Jun 21144,0817,34967,42611,526
31 Dec 20139,2169,14061,38610,751
31 Dec 17101,12410,94343,3233,681
30 Sep 17100,46815,87741,5272,989
30 Jun 1795,94213,61840,3642,727
31 Dec 1687,36310,91339,3832,111
31 Dec 1580,3694,03038,4102,819

Quality Earnings: A006620 has a large one-off gain of ₩7.0B impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: A006620's current net profit margins (6%) are higher than last year (3.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A006620's earnings have grown by 15.4% per year over the past 5 years.

Accelerating Growth: A006620's earnings growth over the past year (124.8%) exceeds its 5-year average (15.4% per year).

Earnings vs Industry: A006620 earnings growth over the past year (124.8%) exceeded the Pharmaceuticals industry 22.3%.

Return on Equity

High ROE: A006620's Return on Equity (13.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 20:38
End of Day Share Price 2024/12/26 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DongKoo Bio & Pharma Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyung Soo KimCape Investment & Securities Co., Ltd.
Kwan Jun RaNH Investment & Securities Co., Ltd.